Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Seegnal to Deploy its Medication Safety Platform Across Nazareth Hospital EMMS, Expanding its Israeli Hospital Footprint

Israeli med-tech SaaS expands domestic footprint while navigating severe liquidity constraints and unproven U.S. commercialization.

By The Northwire Desk — AI Analysis Jun 25, 2026 · 08:30 SEGN · 0.32 Seegnal Inc.
Executive Summary
  • Seegnal Inc. signed a five-year agreement to deploy its clinical decision support SaaS platform at Nazareth Hospital EMMS, a major regional trauma and teaching center in northern Israel.
  • The deployment will support approximately 424 medical staff members (188 physicians and 236 nurses) integrated into routine prescribing workflows.
  • The deal features recurring subscription fees over the initial term with an extension option.
  • The platform is now utilized by approximately 15,000 clinicians across Israeli healthcare settings.
  • The release highlights peer-reviewed clinical performance metrics, including 94% fewer inpatient alerts with 99% specificity and reductions in hospitalizations and medication dispensing.
Material Impact
  • The Nazareth Hospital agreement represents a standard, incremental commercial expansion within Seegnal's established Israeli market. It adds predictable recurring revenue but is immaterial to the company's overall financial profile given its micro-cap status and current cash burn.
  • The deal does not alter the company's fundamental risk profile. It does not address the material going-concern uncertainty, negative working capital, or the need for larger-scale capital raises to fund U.S. expansion and R&D.
  • The clinical metrics cited are consistent with prior management commentary and do not represent new, unexpected data that would re-rate the business model.
SEGN · Price
Company Overview
  • Seegnal Inc. is an Israeli-based med-tech SaaS company developing a clinical decision support system focused on medication safety and prescription intelligence.
  • The platform integrates patient-specific data (medications, lab results, renal function, allergies, age) to deliver context-aware alerts, aiming to reduce alert fatigue, adverse drug events, and hospitalizations.
  • The technology is currently deployed across Israeli healthcare settings, utilized by over 15,000 clinicians, and processes more than 400,000 prescriptions daily.
  • Management is actively pursuing commercial expansion into the United States, targeting long-term care and nursing facilities, while maintaining its core Israeli operations.
Read the original news release →

More from Seegnal Inc.

Jun 19, 2026 · 08:30

Seegnal Successfully Initiates First U.S. Pilot Program

Production / Operations Jun 05, 2026 · 08:30

Seegnal Inc. - AI-Driven Prescription Intelligence Platform for Medication Safety

M&A / Property Jun 02, 2026 · 17:00

Seegnal Raises $1.3M at a Discount to Fund Burn Rate as Filing Delays and Going Concern Risks Mount

Financings May 19, 2026 · 08:30

Seegnal Eyes U.S. Expansion Amid Regulatory Filing Overhang

Other May 06, 2026 · 17:00

Filing Default Lingers as Seegnal Pushes Audit Deadline

Regulatory Apr 30, 2026 · 23:41

Seegnal to miss April 30 financial filing deadline

Regulatory